ISABELLE PHUONG LE M.D
Prescription History 1588807721
Internal Medicine - Hematology & Oncology in Arlington, VA


Quality Rating: 77.89 out of 100 score

NPI Status: Active since April 17, 2009

Contact Information

1100 N GLEBE RD STE 1600
ARLINGTON, VA
ZIP 22201
Phone: (571) 350-8400
Fax: (703) 528-0338

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for ISABELLE PHUONG LE M.D, an active Hematology & Oncology specialist practicing in Arlington, VA. Our medical registry currently tracks 11 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 530 documented patient claims. Among these therapy options, the most frequently utilized medication is Anastrozole, which accounts for 243 claims alone.


Abiraterone Acetate

Generic Formulation: Abiraterone AcetateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
VA State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills37.8
Peer Average Days Supply1,131
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 64.9% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $47,102.97 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,623.31

State Avg Cost Per Claim

$3,036.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.

Therapeutic Applications

This medication is used to treat prostate cancer. Abiraterone belongs to a class of drugs known as anti-androgens (anti-testosterone). Testosterone, a natural hormone, helps prostate cancer to grow and spread. Abiraterone works by blocking the production of testosterone, thereby slowing the growth and spread of prostate cancer. This medication should not be given to women or children.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 243
30-Day Fills 655.2
Days Supply 19,607
VA State Average Benchmarks
Peer Average Claims61.0
Peer Average 30-Day Fills148.3
Peer Average Days Supply4,433
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 298.4% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $14,279.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$58.76

State Avg Cost Per Claim

$28.64

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Aranesp

Generic Formulation: Darbepoetin Alfa In PolysorbatSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 448
VA State Average Benchmarks
Peer Average Claims13.0
Peer Average 30-Day Fills13.7
Peer Average Days Supply250
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $32,100.96 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,006.31

State Avg Cost Per Claim

$1,335.49

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A recombinant protein which stimulates ERYTHROPOIESIS used to treat ANEMIA.

Therapeutic Applications

This medication is used to treat anemia (low red blood cell count) in people with long-term serious kidney disease (chronic kidney failure) and people receiving chemotherapy for some types of cancer (cancer that does not involve the bone marrow or blood cells). Darbepoetin alfa also helps to reduce the need for blood transfusions. It works by signaling the bone marrow to make more red blood cells. This medication is very similar to the natural substance in your body (erythropoietin) that prevents anemia.

Eliquis

Generic Formulation: ApixabanSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
VA State Average Benchmarks
Peer Average Claims73.0
Peer Average 30-Day Fills118.3
Peer Average Days Supply3,347
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 82.2% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,612.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$585.59

State Avg Cost Per Claim

$843.98

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 26
30-Day Fills 54.5
Days Supply 1,635
VA State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills59.2
Peer Average Days Supply1,751
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,255.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$48.29

State Avg Cost Per Claim

$38.24

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Ibrance

Generic Formulation: PalbociclibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 25
30-Day Fills 25.0
Days Supply 700
VA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills22.0
Peer Average Days Supply600
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $402,036.35 across this reporting matrix range.

Provider Avg Cost Per Claim

$16,081.45

State Avg Cost Per Claim

$15,142.88

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Palbociclib is used to treat a certain type of breast cancer. It works by slowing or stopping the growth of cancer cells.

Imbruvica

Generic Formulation: IbrutinibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 48
30-Day Fills 48.0
Days Supply 1,344
VA State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills29.3
Peer Average Days Supply830
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 65.5% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $792,019.82 across this reporting matrix range.

Provider Avg Cost Per Claim

$16,500.41

State Avg Cost Per Claim

$14,350.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (such as mantle cell or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom's macroglobulinemia). Ibrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. Ibrutinib is also used to treat a certain problem that may occur after a stem cell transplant (chronic graft versus host disease). It works by weakening your body's defense system (immune system).

Letrozole

Generic Formulation: LetrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 49
30-Day Fills 121.0
Days Supply 3,630
VA State Average Benchmarks
Peer Average Claims59.0
Peer Average 30-Day Fills137.4
Peer Average Days Supply4,107
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,837.92 across this reporting matrix range.

Provider Avg Cost Per Claim

$37.51

State Avg Cost Per Claim

$37.41

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Prednisone

Generic Formulation: PrednisoneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 17
30-Day Fills 24.0
Days Supply 693
VA State Average Benchmarks
Peer Average Claims47.0
Peer Average 30-Day Fills56.5
Peer Average Days Supply1,001
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 63.8% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $119.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.04

State Avg Cost Per Claim

$6.74

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Tamoxifen Citrate

Generic Formulation: Tamoxifen CitrateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 64
30-Day Fills 170.0
Days Supply 5,100
VA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills76.7
Peer Average Days Supply2,292
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 100.0% higher than the standard regional baseline profile for VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,543.28 across this reporting matrix range.

Provider Avg Cost Per Claim

$39.74

State Avg Cost Per Claim

$35.03

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Therapeutic Applications

Tamoxifen is used to treat breast cancer. It is also used to reduce the chances of breast cancer in high-risk patients. This medication can block the growth of breast cancer. It works by interfering with the effects of estrogen in the breast tissue.

Xarelto

Generic Formulation: RivaroxabanSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 16
30-Day Fills 43.0
Days Supply 1,290
VA State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills64.4
Peer Average Days Supply1,847
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 55.6% less volume than the regional standard for practitioners inside VA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $24,423.71 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,526.48

State Avg Cost Per Claim

$925.34

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Therapeutic Applications

Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like ISABELLE PHUONG LE M.D provides transparency into local medical care patterns within Arlington, VA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.